Today's pre-market stock movers: CHWY, PATH, SNAP, HPE and more

Moomoo Breakfast USwrote a column06/02/2022 20:27

Gainers:

• $Repare Therapeutics(RPTX.US)$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)

• $Chewy(CHWY.US)$+19.8% (Chewy stock soars on earnings. Here's what really mattered)

• $UiPath(PATH.US)$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)

• $Pure Storage(PSTG.US)$ +10.6% (In reaction to earnings)

• $Credo Technology(CRDO.US)$ +10.2% (In reaction to earnings)

• $Blue Apron(APRN.US)$ +9.4% (launches new meal kit offering on )Walmart.com

• $MongoDB(MDB.US)$ +9.2% (In reaction to earnings)

• $Nextdoor Holdings(KIND.US)$ +7.1% (authorizes new $100 mln share repurchase program)

• $Elastic(ESTC.US)$ +6.5% (In reaction to earnings)

• $Sana Biotechnology(SANA.US)$ +5.6% (to develop manufacturing facility in Bothell)

• $Veeva Systems(VEEV.US)$ +4.3%(In reaction to earnings)

• $PVH Corp(PVH.US)$ +4.1% (also increases planned 2022 share repurchases to $400 mln),

• $Designer Brands(DBI.US)$ +4% (In reaction to earnings)

• $NetApp(NTAP.US)$+3.4% (In reaction to earnings)

• $Secureworks(SCWX.US)$ +3.3% (In reaction to earnings)

• $SpartanNash(SPTN.US)$ +2.9% (In reaction to earnings)

• $Comtech Telecommunications(CMTL.US)$ +2.7% (receives 5G contract with mobile network operator in Saudi Arabia)

• $ANI Pharmaceuticals(ANIP.US)$ +2.5% (receives FDA approval for ANDA for Fludrocortisone Acetate Tablets)

• $Ferroglobe(GSM.US)$ +2.5% (names new COO)

• $ASGN Inc(ASGN.US)$ +2.3% (acquires GlideFast Consulting for $350 mln; reaffirms Q2 outlook)

• $Riot Platforms(RIOT.US)$ +1.5% (names new CFO)

• $DHI Group(DHX.US)$+1.4% (US PTO issues patent related to taxonomy)

• $Silk Road Medical(SILK.US)$ +1.3% (CMS has expanded coverage for TCAR to include standard surgical risk patients within the VQI's TCAR

• $Cedar Fair(FUN.US)$+1.1% (YTD update)

• $Boyd Gaming(BYD.US)$+1.1% (authorizes $500 mln increase to share repurchase program)

• $Semtech(SMTC.US)$+1% (In reaction to earnings)

• $Descartes Systems Group(DSGX.US)$ +0.9% (In reaction to earnings)

• $GameStop(GME.US)$+0.8% (In reaction to earnings)

Analyst comments:

• $SolarEdge Technologies(SEDG.US)$ +3.5% (upgraded to Outperform from Perform at Oppenheimer)

• $Wolfspeed(WOLF.US)$ +3.5% (upgraded to Outperform from Perform at Oppenheimer)

• $Ecolab(ECL.US)$+1.6% (upgraded to Buy from Neutral at UBS)

• $Americold Realty Trust(COLD.US)$ +1.4% (upgraded to Neutral from Underperform at BofA Securities)

• $Agree Realty Corp(ADC.US)$ +1.3% (upgraded to Buy from Neutral at BofA Securities)

• $Dentsply Sirona(XRAY.US)$+1.1% (upgraded to Buy from Neutral at UBS)

Losers:

• $Immunic(IMUX.US)$ -62.2% (reported top-line data from its phase 2 CALDOSE-1 trial of lead asset, vidofludimus calcium)

• $C3.ai(AI.US)$-19.4%(In reaction to earnings)

• $Ozon Holdings(OZON.US)$ -19% (enters into standstill agreement for $750 mln convertible bonds)

• $Centessa Pharmaceuticals(CNTA.US)$-8.9% (to discontinue clinical development of lixivaptan for Autosomal Dominant Polycystic Kidney Disease)

• $Hewlett Packard Enterprise(HPE.US)$-5.5% (earnings and sales miss amid 'inflationary environment and ongoing supply-chain disruptions')

• $Concert Pharmaceuticals(CNCE.US)$ -5% (prices offering of 10 mln shares of common stock at $4.75 per share)

•$Magnolia Oil & Gas(MGY.US)$ -4.7% (announces proposed block trade of 7.5 mln Class A shares by selling shareholders; intends to purchase 2 mln Class B shares)

• $Blue Owl Capital(OWL.US)$ -3.1% (prices secondary offering by NBSH Blue Investments II of 10,698,180 shares of Class A common stock at $11.50 per share)

• $American Tower Corp(AMT.US)$-2.9% (intends to offer 8,350,000 shares of its common stock in a registered public offering)

• $Ciena(CIEN.US)$-2.8% (In reaction to earnings)

• $International Game Technology(IGT.US)$-1.7% (signs ten year contract extension with Kansas lottery)

• $SentinelOne(S.US)$ -1.7% (In reaction to earnings)

• $Moderna(MRNA.US)$ -1.4% (Moderna and EC to amend their originally agreed contractual delivery schedules for the Moderna COVID-19 vaccine booster product (Spikevax, mRNA-1273) or updated booster vaccine candidate)

• $ArcBest(ARCB.US)$ -1.3% (guidance update)

• $Enochian Biosciences(ENOB.US)$ -1.2% (published on its website a letter to shareholders to clarify "several misrepresentations")

• $Radius Health(RDUS.US)$ -1.1% (provides update on abaloparatide transdermal system; to cease all work on abalo-TDS)

• $Day One Biopharmaceuticals(DAWN.US)$ -0.9% (files for $400 mln mixed securities shelf offering)

Analyst comments:

• $Pinterest(PINS.US)$ -2.7% (downgraded to Neutral from Overweight at Piper Sandler)

• $Twilio(TWLO.US)$ -2.7% (downgraded to Equal Weight from Overweight at Barclays)

• $Albemarle(ALB.US)$-2.3% (downgraded to Neutral from Buy at UBS)

• $Snap Inc(SNAP.US)$ -1.8% (downgraded to Neutral from Overweight at Piper Sandler)

• $Crown Castle(CCI.US)$-1.6% (downgraded to Underweight from Equal Weight at Wells Fargo)

• $Starry Group(STRY.US)$ -1.6% (downgraded to Neutral from Buy at Goldman)

Moomoo is an app offered by Moomoo Technologies Inc. that provides information about investments. Moomoo Technologies is not an investment adviser or a broker-dealer and it provides neither investment or financial advice nor securities trading services. All contents such as comments and links posted or shared by users of the community are opinions of the respective authors only and do not reflect the opinions, views, or positions of Moomoo Technologies, its affiliates, or any employees of Moomoo Technologies or its affiliates. You are advised to consult a qualified financial or tax advisor for your personal financial planning and tax situations. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

605K Views

Comment

Report

Moomoo Breakfast US

Posts 1887Followers50K

ColumnBefore the Bell | Consumer spending gains seen as cooling

Comment